Assyro Team
16 min read
Nitrosamine Control Strategy: From Risk Assessment to Confirmatory Testing
Quick Answer
A nitrosamine control strategy is the documented plan for preventing, detecting, and controlling nitrosamine impurities in pharmaceutical products. It encompasses root cause evaluation of amine + nitrite sources, process controls to prevent formation, validated analytical methods (primarily LC-MS/MS with sensitivity to 10% of acceptable intake limits), confirmatory testing of representative batches, and ongoing monitoring. FDA and EMA require control strategies to prioritize root cause elimination over end-product testing.
Key Takeaways
Key Takeaways
- FDA and EMA both require control strategies to prioritize root cause elimination of nitrosamine formation over end-product testing.
- Validated analytical methods (primarily LC-MS/MS) must demonstrate sensitivity to 10% of the applicable acceptable intake limit.
- Control strategies must address both drug substance-related nitrosamines and drug product-related nitrosamines formed during formulation or storage.
- Ongoing monitoring and lifecycle management are required; control strategies must be updated when manufacturing changes occur or new formation pathways are identified.
- A nitrosamine control strategy translates the findings of a risk assessment into actionable manufacturing controls, analytical methods, and specifications that ensure nitrosamine levels remain below acceptable intake (AI) limits throughout a product's lifecycle.
- The distinction between a risk assessment and a control strategy matters. A risk assessment identifies what could happen — which nitrosamines might form and through which pathways. A control strategy defines what you will do about it — the specific process modifications, material controls, analytical methods, and specifications that prevent or detect nitrosamine contamination.
- Regulatory agencies evaluate control strategies for both completeness and hierarchy of controls. A strategy that relies solely on end-product testing without addressing root causes will face scrutiny. FDA and EMA both emphasize that the preferred approach is eliminating the root cause of nitrosamine formation, with testing serving as a verification measure rather than the primary control.
- In this guide, you'll learn:
- Root cause evaluation methodology for nitrosamine formation
- Risk factor analysis for amine and nitrite sources
- Process control implementation strategies
- Analytical method requirements for confirmatory testing
- AI limits for specific nitrosamines (NDMA, NDEA, NMBA, and others)
- FDA and EMA regulatory timelines and submission requirements
- ---
Root Cause Evaluation
Root cause evaluation identifies the specific chemical and process-level mechanisms that allow nitrosamine formation. This goes beyond identifying whether amines and nitrites are present — it determines why they come into contact and under what conditions nitrosation occurs.
The Nitrosamine Formation Equation
Nitrosamines form when three conditions are met simultaneously:
Each component must be evaluated independently and in combination.
Amine Source Identification
| Amine Source | Examples | Risk Level | Control Approach |
|---|---|---|---|
| API structure | Secondary amines in ranitidine, metformin, rifampicin | High | NDSRI assessment; reformulation if feasible |
| Process intermediates | Dimethylamine from DMF degradation; diethylamine from TEA use | High | Solvent substitution; process redesign |
| Starting materials | Amine-containing starting materials with residual levels | Medium | Starting material specification; purge validation |
| Excipients | Croscarmellose sodium, povidone, sodium starch glycolate | Medium | Excipient supplier qualification; alternative excipient evaluation |
| Degradation products | Amine-bearing degradants from API or excipient breakdown | Medium | Stability monitoring; packaging optimization |
| Container closure | Amine migration from rubber stoppers, cap liners | Low-Medium | E&L studies; alternative closure systems |
Nitrosating Agent Source Identification
| Nitrosating Source | Examples | Risk Level | Control Approach |
|---|---|---|---|
| Sodium nitrite reagent | Direct use in API synthesis (e.g., diazotization reactions) | Critical | Process redesign; alternative reagents |
| Recycled solvents | Nitrite/nitrate accumulation in recovery operations | High | Dedicated solvents; recycling controls |
| Water | Nitrate/nitrite in purified water or WFI | Medium | Water system monitoring; nitrite specification |
| Excipients | Nitrite contamination in starch, cellulose derivatives | Medium | Excipient nitrite testing; supplier qualification |
| Gaseous NOx | Ambient nitrogen oxides; process atmosphere | Low-Medium | Inerting; environmental controls |
| Packaging | Nitrite leaching from rubber components | Low | E&L qualification; nitrite-free materials |
Favorable Conditions Analysis
| Condition | Nitrosation Promotion | Mitigation |
|---|---|---|
| Acidic pH (< 4) | Optimal for nitrosation kinetics | pH control > 4 where possible |
| Elevated temperature (> 60C) | Accelerates reaction kinetics | Temperature control; minimize thermal exposure |
| Prolonged contact time | Increases cumulative exposure | Process time limits; rapid processing |
| Aqueous environment | Facilitates ionic nitrosation | Minimize aqueous steps; dry processing |
| Catalytic metals | Certain metal ions catalyze nitrosation | Equipment qualification; metal-free vessels |
Process Control Implementation
Hierarchy of Controls
FDA and EMA both endorse a hierarchy of controls approach, prioritizing elimination over detection:
Level 1: Eliminate Root Cause (Most Preferred)
| Strategy | Implementation | Documentation |
|---|---|---|
| Remove nitrosating agent from process | Replace sodium nitrite with alternative reagent; use fresh solvents instead of recycled | Process change documentation; batch record update |
| Remove vulnerable amine from process | Alternative synthetic route; substitute reagents | Route change justification; regulatory filing |
| Switch to nitrite-free excipients | Qualify alternative excipient or nitrite-free grade | Excipient qualification report; stability data |
| Replace container closure | Nitrite-free rubber formulation; alternative closure | E&L study; stability data with new closure |
Level 2: Process Controls (Preferred)
| Strategy | Implementation | Documentation |
|---|---|---|
| pH control | Maintain pH > 4 during manufacturing steps where amines and nitrites could interact | In-process pH monitoring; batch record limits |
| Temperature control | Limit thermal exposure during vulnerable process steps | Temperature recording; validated ranges |
| Inerting | Nitrogen atmosphere to exclude NOx | Atmosphere monitoring; oxygen limits |
| Dedicated equipment | Prevent cross-contamination from previous campaigns | Equipment dedication policy; cleaning validation |
| Water system controls | Nitrite specification for process water (< 0.1 ppm) | Water monitoring program; trend analysis |
Level 3: Purification Controls
| Strategy | Implementation | Documentation |
|---|---|---|
| Additional washing steps | Aqueous washes to remove nitrosamine from organic phase | Process validation; purge factor data |
| Recrystallization | Additional crystallization to reduce impurity levels | Process development data; purge validation |
| Chromatographic purification | Column purification to remove specific nitrosamines | Method development; scale-up validation |
| Activated carbon treatment | Adsorptive removal of nitrosamines | Treatment validation; breakthrough studies |
Level 4: Specification and Testing (Least Preferred Alone)
| Strategy | Implementation | Documentation |
|---|---|---|
| Drug substance specification | Set limit at or below AI/MDD-derived specification | Validated analytical method; batch data |
| Drug product specification | Set limit at or below AI/MDD-derived specification | Validated analytical method; batch data |
| In-process testing | Test at critical manufacturing steps | Method validation; sampling plan |
| Batch release testing | Test every batch before release | Method validation; OOS investigation procedure |
Pro Tip
FDA reviewers will specifically ask why root cause elimination was not chosen if your control strategy relies primarily on Level 3 or Level 4 controls. Prepare a documented justification explaining why Level 1 or Level 2 controls are not technically feasible for your specific product and process. "Cost" alone is not an acceptable justification.
Analytical Methods for Nitrosamine Testing
LC-MS/MS: The Primary Method
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the preferred analytical technique for nitrosamine quantification due to its sensitivity, selectivity, and multi-analyte capability.
Method requirements per FDA expectations:
| Parameter | Requirement | Rationale |
|---|---|---|
| Sensitivity (LOQ) | ≤ 10% of AI limit (adjusted for daily dose) | Must detect nitrosamines well below the specification |
| Specificity | Demonstrate separation from matrix interferences; use MRM transitions | Prevent false positives from co-eluting compounds |
| Linearity | R² ≥ 0.99 across range from LOQ to 200% of specification | Ensure accurate quantification across working range |
| Accuracy | 80-120% recovery at LOQ; 90-110% at specification level | Matrix effects must not suppress or enhance signal |
| Precision | RSD ≤ 20% at LOQ; ≤ 10% at specification level | Repeatable results within and between laboratories |
| Sample preparation | Appropriate for matrix (API, drug product, excipient) | Method must account for extraction efficiency |
Common LC-MS/MS configurations:
| Configuration | Application | Advantages |
|---|---|---|
| Reversed-phase LC + ESI+ MRM | Standard nitrosamine panel (NDMA, NDEA, NMBA, etc.) | Broad applicability; commercially available standards |
| HILIC + ESI+ MRM | Polar nitrosamines (NMEA, NMOR) | Better retention of polar analytes |
| GC-MS headspace | Volatile nitrosamines (NDMA, NDEA) in simple matrices | Very low detection limits for volatile species |
| GC-MS/MS | Complex matrices requiring additional selectivity | Enhanced specificity for challenging samples |
Multi-Analyte Method Design
A comprehensive nitrosamine method should simultaneously quantify all relevant nitrosamines based on the risk assessment:
| Analyte | MRM Transition (Typical) | AI (ng/day) | Typical LOQ Target |
|---|---|---|---|
| NDMA | 75 > 43 (quantifier); 75 > 58 (qualifier) | 96 | 2-5 ppb |
| NDEA | 103 > 75 (quantifier); 103 > 47 (qualifier) | 26.5 | 1-3 ppb |
| NMBA | 147 > 117 (quantifier); 147 > 73 (qualifier) | 96 | 2-5 ppb |
| NIPEA | 117 > 75 (quantifier); 117 > 43 (qualifier) | 26.5 | 1-3 ppb |
| NDIPA | 131 > 89 (quantifier); 131 > 43 (qualifier) | 26.5 | 1-3 ppb |
| NDBA | 159 > 103 (quantifier); 159 > 57 (qualifier) | 26.5 | 1-3 ppb |
| NMPA | 137 > 107 (quantifier); 137 > 66 (qualifier) | 26.5 | 1-3 ppb |
Method Validation Considerations
| Consideration | Challenge | Solution |
|---|---|---|
| Matrix effects | Drug substance or excipients can suppress/enhance ionization | Use isotopically labeled internal standards (d6-NDMA, d10-NDEA) |
| Artifact formation | Nitrosamines may form during sample preparation | Minimize acidic conditions; use cold sample processing |
| Cross-contamination | Sub-ppb levels are susceptible to laboratory contamination | Dedicated glassware; avoid DMF/DMA in mobile phases |
| Stability | Some nitrosamines degrade under light or elevated temperature | Process samples same day; protect from light; refrigerate |
| Reference standards | Certified standards required for each target analyte | Use certified reference materials (CRMs) from qualified suppliers |
Pro Tip
Artifact formation during sample preparation is a well-documented problem in nitrosamine analysis. If your sample preparation involves acidification of amine-containing matrices, you may generate nitrosamines in the sample solution that were not present in the original product. Always include control experiments (amine-containing matrix without nitrite, and nitrite-containing matrix without amine) to verify that no artifacts are formed during analysis.
Acceptable Intake Limits and Specification Setting
AI Limits for Specific Nitrosamines
| Nitrosamine | AI (ng/day) | Basis | Specification Calculation |
|---|---|---|---|
| NDMA | 96 | Compound-specific carcinogenicity data | AI / MDD (g) = limit in ppm |
| NDEA | 26.5 | Compound-specific carcinogenicity data | AI / MDD (g) = limit in ppm |
| NMBA | 96 | Compound-specific carcinogenicity data | AI / MDD (g) = limit in ppm |
| NIPEA | 26.5 | Compound-specific carcinogenicity data | AI / MDD (g) = limit in ppm |
| NDIPA | 26.5 | Compound-specific carcinogenicity data | AI / MDD (g) = limit in ppm |
| NDBA | 26.5 | Compound-specific carcinogenicity data | AI / MDD (g) = limit in ppm |
| NMPA | 26.5 | Compound-specific carcinogenicity data | AI / MDD (g) = limit in ppm |
| NMEA | 26.5 | Compound-specific carcinogenicity data | AI / MDD (g) = limit in ppm |
| NMOR | 26.5 | Compound-specific carcinogenicity data | AI / MDD (g) = limit in ppm |
| Uncharacterized | 18 | Cohort of concern TTC | 18 ng / MDD (g) = limit in ppm |
Specification Setting Worked Example
Product: Oral tablet, MDD = 320 mg (0.32 g), chronic use (lifetime exposure)
| Nitrosamine | AI (ng/day) | Specification (ppm) | Specification (ng/tablet) |
|---|---|---|---|
| NDMA | 96 | 96 / 0.32 = 300 ppb | 96 ng |
| NDEA | 26.5 | 26.5 / 0.32 = 82.8 ppb | 26.5 ng |
LOQ requirement for NDEA: ≤ 10% of 82.8 ppb = ≤ 8.3 ppb
Multiple Nitrosamines in a Single Product
When multiple nitrosamines are detected or at risk, FDA permits two approaches:
- Individual limits: Each nitrosamine controlled at its own AI-based specification (preferred)
- Aggregate control: Total nitrosamine content controlled if individual species are at very low levels relative to their AI limits
When using aggregate control, the contribution of each nitrosamine must be expressed as a fraction of its individual AI, and the sum must not exceed 1.0:
FDA and EMA Regulatory Timelines
FDA Timeline and Submission Requirements
| Milestone | FDA Expectation | Submission Vehicle |
|---|---|---|
| Risk assessment completion | Within 3 years of September 2020 guidance (by September 2023) | Not submitted unless requested |
| Confirmatory testing | For medium/high-risk products; completed as part of risk assessment | Retained for inspection |
| Control strategy implementation | For products where nitrosamines detected above 10% AI | SUPAC supplement (CBE-30 or PAS) |
| Specification addition | If nitrosamine specification added to drug substance or product | PAS (Prior Approval Supplement) for new specification |
| Process change | If manufacturing process modified to eliminate root cause | CBE-30 or PAS depending on change scope |
| Labeling update | Generally not required unless safety communication needed | CBE supplement |
EMA Timeline and Variation Requirements
| Milestone | EMA Expectation | Variation Type |
|---|---|---|
| Step 1: Risk evaluation | Completed by March 2021 (biologicals by July 2021) | Not submitted; retained for inspection |
| Step 2: Confirmatory testing | Completed by September 2023 (biologicals by July 2024) | Results retained |
| Step 3: Outcome reporting | If nitrosamines detected, submit variation | Type IB or Type II depending on findings |
| Change in specification | New nitrosamine specification | Type II variation |
| Process change | Manufacturing modification | Type IB or Type II variation |
| Change in finished product | Reformulation to eliminate risk | Type II variation |
Key Differences Between FDA and EMA Approaches
| Aspect | FDA | EMA |
|---|---|---|
| Scope | All drug products; expanded to all drug classes in 2023 | All medicinal products including biologicals |
| Risk assessment trigger | Vulnerable chemistries (amines + nitrosating conditions) | Broader: includes evaluation of all products |
| AI limit source | FDA-published AI table | Same AI values; derived from same carcinogenicity data |
| Submission requirement | SUPAC supplement for changes; risk assessment retained | Variation procedure for changes; Step 1/2 results reported |
| Interim limits | FDA initially permitted temporary higher limits during transition | EMA set clear deadline milestones |
| NDSRI approach | Explicit CPCA framework published | Aligned with FDA approach; cross-referenced guidance |
Confirmatory Testing Protocol
Batch Selection
| Selection Criterion | Minimum Requirement | Rationale |
|---|---|---|
| Number of batches | Minimum 3 commercial-scale batches | Statistical representation of process variability |
| Batch age | Include recent and retention samples | Assess both initial levels and formation over time during stability testing |
| Process representation | Include batches from all manufacturing sites | Site-specific process differences |
| Stability samples | Accelerated and long-term stability samples if available | Assess nitrosamine formation during storage |
Testing Protocol
- Sample preparation: Follow validated method; include matrix-matched standards and isotopically labeled internal standards
- System suitability: Verify instrument performance meets method requirements before each batch
- Bracketing: Include calibration standards at beginning and end of each analytical run
- Duplicate analysis: Analyze each sample in at least duplicate
- Control samples: Include blank (matrix without nitrosamine), positive control (spiked at specification level), and negative control (solvent blank)
Result Interpretation and Action
| Finding | Action Required | Regulatory Filing |
|---|---|---|
| All results < 10% of AI | Document results; no specification required; ongoing monitoring recommended | No filing required |
| Any result 10-100% of AI | Implement control strategy; set specification at AI; batch release testing | CBE-30 (FDA) or Type IB (EMA) |
| Any result > AI | Root cause investigation; immediate corrective action; evaluate patient risk | PAS (FDA) or Type II (EMA); possible market action |
Key Takeaways
References
Key Takeaways
- 1. Control strategy hierarchy matters: FDA and EMA both prefer root cause elimination over testing-only strategies. Document why higher-level controls are not feasible if you rely on specification and testing.
- 2. Identify all sources: Evaluate amines from API, excipients, degradation, and packaging. Evaluate nitrosating agents from reagents, water, solvents, and excipients. Evaluate conditions (pH, temperature, time) that promote nitrosation.
- 3. LC-MS/MS is the standard: Achieve LOQ at or below 10% of the AI-based specification. Use isotopically labeled internal standards to correct for matrix effects.
- 4. Prevent analytical artifacts: Nitrosamines can form during sample preparation if amine-containing matrices are exposed to acidic conditions. Include artifact control experiments.
- 5. AI limits are compound-specific: NDMA (96 ng/day) and NDEA (26.5 ng/day) have different limits. Uncharacterized nitrosamines default to the cohort of concern TTC of 18 ng/day.
- 6. Test representative batches: Minimum 3 commercial batches plus stability samples. Include batches from all manufacturing sites.
- 7. Regulatory pathways differ: FDA uses SUPAC supplements (CBE-30 or PAS). EMA uses variation procedures (Type IB or Type II). Plan the regulatory filing before implementing the control strategy.
- ---
- FDA Guidance: "Control of Nitrosamine Impurities in Human Drugs" (Version 3.0, March 2023)
- FDA Updated Table of Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (2023)
- EMA Questions and Answers on Nitrosamine Impurities (Updated 2023)
- EMA Article 5(3) Referral: Lessons Learned from Nitrosamine Impurities
- ICH M7(R1): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals
- ICH Q9(R1): Quality Risk Management
- 21 CFR 314.70: Supplements and Other Changes to an Approved NDA
- USP General Chapter <1469>: Nitrosamine Impurities